Double Blind Placebo-Controlled Phase I/II Clinical Trial of Idebenone in Patients With Primary Progressive Multiple Sclerosis

Trial Profile

Double Blind Placebo-Controlled Phase I/II Clinical Trial of Idebenone in Patients With Primary Progressive Multiple Sclerosis

Completed
Phase of Trial: Phase I/II

Latest Information Update: 05 Mar 2018

At a glance

  • Drugs Idebenone (Primary)
  • Indications Multiple sclerosis
  • Focus Therapeutic Use
  • Acronyms IPPOMS
  • Most Recent Events

    • 05 Mar 2018 According to a Santhera Pharmaceuticals media release, There was no difference in the occurrence and severity of adverse events between the treatment groups indicating that idebenone at a daily dose of 2,250 mg was well tolerated.
    • 30 Jan 2018 Planned primary completion date changed from 1 Jan 2018 to 1 Aug 2018.
    • 29 Jan 2018 According to a Santhera Pharmaceuticals media release, Top line study results of the trial which was carried out in collaboration with the U.S. National Institute of Neurological Disorders and Stroke (NINDS) are expected to be announced in Q1 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top